Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2001

View Archived Issues

Human Genome Sciences makes significant progress in several areas during 2000

Karo Bio provides company update

Alliance to develop allergy treatments established by Maxygen and ALK-Abello

FDA requests further information for Campath BLA

Vita-Invest's combination therapy for hypertension completes phase III

GlaxoSmithKline and Sepsicure establish agreement for sepsis treatment

Novel asthma gene identified as part of joint scientific collaboration

Telik's TLK-286 completes phase I evaluation

FDA accepts AHP's PMA for unique bone growth protein

Phase I/II program for NBI-6024 expanded; pivotal phase IIb trial to commence later this year

Adipose tissue hormone reduces body weight by increasing FFA oxidation

Avant reports preliminary results of phase I extension trial for cholesterol management vaccine

Patient enrollment complete in phase III trial of beraprost for intermittent claudication

Adenoviral gene transfer of eNOS for improving age-related erectile dysfunction

Rifabutin-based triple regimen as rescue therapy for resistant H. pylori infection

Vion cleared to proceed with clinical trial of anticancer agent VNP-40101M

Esomeprazole effective for maintaining healing of erosive esophagitis; receives major approval

CuraGen and Bayer cleared to proceed with landmark genomic agreements

Japanese introduction announced for new atypical antipsychotic

Securiosides selectively cytotoxic to M-CSF-stimulated macrophages

Resveratrol reported to have selective antibacterial activity against Neisseria

HIV vaccines comprising adenoviral vector and gag genes described by Merck

Texas university researchers identify PEA3 as a tumor suppressor for cancer treatment

Potent antibacterial group A streptogramin derivatives designed at Aventis

Fujisawa discloses inhibitors of NO production

Selective ETA receptor ligands and their use reported by Pfizer scientists

Novel antipruritic agents in development at Pfizer